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DeubiquitylationThe members of the transforming growth factor beta (TGFβ) family of cytokines, including bonemorphogenetic
proteins (BMP), play fundamental roles in development and tissue homeostasis. Hence, aberrant TGFβ/BMP sig-
nalling is associated with several human diseases such as ﬁbrosis, bone and immune disorders, cancer progres-
sion and metastasis. Consequently, targeting TGFβ signalling for intervention potentially offers therapeutic
opportunities against these diseases. Many investigations have focussed on understanding the molecular mech-
anisms underpinning the regulation of TGFβ signalling. One of the key areas has been to investigate the regula-
tion of the protein components of the TGFβ/BMP signal transduction pathways by ubiquitylation and
deubiquitylation. In the last 15 years, extensive research has led to the discovery and characterisation of several
E3 ubiquitin ligases that inﬂuence the TGFβ pathway. However, the research on DUBs regulating the TGFβ path-
way has received prominence only recently and is still an emerging ﬁeld. This reviewwill provide a concise sum-
mary of our current understanding of how DUBs regulate TGFβ signalling.
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The TGFβ family of cytokines comprises some40members including
the bone morphogenetic protein (BMP) and controls a plethora of
context-dependent cellular processes including proliferation,
2187L. Herhaus, G.P. Sapkota / Cellular Signalling 26 (2014) 2186–2192differentiation, extracellular matrix production, motility, survival and
fate. Abnormal TGFβ signalling is linked to themanifestation ofmultiple
human diseases, including ﬁbrosis, immune disorders and cancer [1–4].
TGFβ signalling is initiatedwhen the ligands bind to a pair of cognate re-
ceptor serine/threonine protein kinases (termed type I and type II) on
the cell surface. This triggers the phosphorylation of intracellular recep-
tor regulated SMAD transcription factors (R-SMADs) by type I receptor
kinases [5]. TGFβ ligands are divided into two subfamilies: the TGFβ
subfamily, which primarily signals through the phosphorylation of
SMADs 2 and 3, and the BMP subfamily, which signals through SMADs
1/5/8 [5] (Fig. 1). In the canonical pathway, the phosphorylated R-
SMADs interact with SMAD4 and translocate to the nucleus, where to-
gether with other co-factors they regulate the transcription of over
500 target genes [5–7]. The context-dependent transcriptional pro-
gramme driven by the TGFβ signals modulates cell behaviour [8–10].
The powerful action of TGFβ cytokines in cells and tissues is tightly
regulated. Complex biochemical mechanisms have evolved to intricate-
ly control the extent, duration and potency of signalling in response to
TGFβ cytokines. From secreted molecules that act as ligand traps
to eventual transcriptional events that provide positive or negative
feedback, complex regulatory inputs establish a dynamic ﬁne-tuning
of the TGFβ pathway [11,12]. Regulation is also achieved through the
addition or removal of post-translational modiﬁcations, such as phos-
phorylation and ubiquitylation, on core protein components of the
TGFβ signalling pathway that alters their activity or stability [13,14].SMAD4
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Fig. 1. An overview of the core-components of TGFβ/BMP signalling. Ligand binding to serine/t
formation of type I and type II receptors. When in close proximity, the type II receptor kinase ph
can then phosphorylate R-SMADs at their conserved C-termini. TGFβ ligands induce the phosph
phorylated R-SMADs are then able to form a complexwith SMAD4. The R-SMAD–SMAD4 comp
Inhibitory SMADs (SMAD6/7) are also transcribed and act in a feedback loop, as SMAD6/7 com
lation of receptor ubiquitylation.The regulatory inputs collectively shape and deﬁne the nature of cellular
responses to TGFβ/BMP signals in diverse biological processes and con-
texts. Understanding the molecular details of how TGFβ signalling is
regulated in cells could be key to unravelling new opportunities for
therapeutic intervention against diseases associated with abnormal
signalling.
Reversible ubiquitylation of key components of the TGFβ pathway,
including the type I TGFβ/BMP receptor kinases and SMADs, is known
to play a critical role in regulating the outcome of TGFβ signalling
[14–19]. Much is known about the roles of various E3 ubiquitin ligases
in regulating their stability. However, investigations into the regulation
of the TGFβ/BMP pathways by DUBs primarily constitute recent prog-
ress and are still emerging.
2. Ubiquitylation of the TGFβ/BMP pathway components
Ubiquitylation is a reversible post-translational modiﬁcation that
is essential in many cellular regulatory mechanisms [20,21]. During
the ubiquitylation cascade, ubiquitin is attached to target proteins
through the concerted actions of an E1-ubiquitin activating enzyme,
an E2-ubiquitin conjugating enzyme and an E3-ubiquitin ligase. This
cascade is initiated by the ATP dependent activation of ubiquitin by
the E1. The E1 links the C-terminal glycine residue of ubiquitin via
a thioester bond to a cysteine residue within its active site. The acti-
vated ubiquitin intermediate is then transferred to a cysteine residuetranscription
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osphorylates and activates the type I receptor kinase. The activated type I receptor kinase
orylation of SMAD2/3, whereas BMP ligands promote SMAD1/5/8 phosphorylation. Phos-
lex travels to the nucleus where TGFβ/BMP-mediated target gene transcription is initiated.
pete with R-SMADs for receptor binding and bind to E3 ligases and/or DUBs for the regu-
Table 1
DUBs in the TGFβ/BMP signalling pathway.
DUB Mode of action
A20 Inhibits non-canonical TGFβ signalling via the TRAF6–TAK1–p38 MAPK/
JNK pathway [74].
AMSH AMSH prolongs BMP signalling by sequestering SMAD6 [67].
AMSH-
LP
AMSH-LP prolongs TGFβ signalling by sequestering SMAD7 [68].
CYLD CYLD deubiquitylates SMAD7 [52] and AKT [53].
OTUB1 OTUB1 inhibits the ubiquitylation of active pSMAD2/3 [54].
UCH37 UCH37 associates with SMAD7 and ALK5 and inﬂuences TGFβ-mediated
transcription [65,66].
USP4 USP4 deubiquitylates ALK5 [41] and TAK1 [71].
USP9X USP9X reverses monoubiquitylation of SMAD4 [48,49].
USP11 USP11 deubiquitylates ALK5 [42].
USP15 USP15 deubiquitylates ALK3 [45], ALK5 [43] and monoubiquitylated
R-SMADs [47].
USP18 USP18 deubiquitylates the TAK1–TAB1 complex [73].
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enzymes, which determine the type of the ubiquitin chain linkage
that is assembled on the substrate. The ubiquitin-loaded E2 then
pairs with speciﬁc E3-ubiquitin ligases, which facilitates the conju-
gation of C-terminal glycine of ubiquitin via an isopeptide bond to
the ε-amino group of the target lysine on the substrate protein,
which can be ubiquitin itself. More than 600 E3 ubiquitin ligases
are encoded in the human genome, and in certain cases their associ-
ated substrate adaptor proteins often recruit substrates, thereby pro-
viding speciﬁcity in the ubiquitylation process [22–26]. Target
proteins can be monoubiquitylated, multi-monoubiquitylated or by
repeated action of the E1, E2 and E3 ligases ubiquitin can be added
onto one of several lysine residues or the α-amino group of the at-
tached ubiquitin to form unique polyubiquitin chains. The nature of
ubiquitylation on the target protein deﬁnes its fate, from altered sub-
cellular localisation or activity to destruction through the protea-
some or lysosome [27–29].
The E3 ubiquitin ligases involved in the ubiquitylation of TGFβ path-
way components have been reviewed extensively [14,15,17,30–32]
(Fig. 1). However, very little is known about the E2 enzymes that are in-
volved in the ubiquitylation of TGFβ pathway components, with
UBE2L3 and UBE2O the only members implicated [33,34]. Furthermore,
the precise ubiquitylation sites on most of the TGFβ pathway compo-
nents known to be ubiquitylated have not been established at the en-
dogenous level. Other than the K48-linked ubiquitin chains that
mostly confer destructive fate on target proteins, there has been a lack
of comprehensive linkage-type analyses on polyubiquitin chains on
the TGFβ-pathway components. Similarly, whether and how these
chains are recognised by potential ubiquitin-binding proteins, that
then modulate the fate of the target protein, remain to be deﬁned.
3. Regulation of the TGFβ/BMP pathway components
by deubiquitylating enzymes
The functional consequences of ubiquitylation of the TGFβ pathway
components can be reversed by the action of deubiquitylating enzymes
that remove the ubiquitin or ubiquitin chains attached to the target
protein. Similarly, the prevention of ubiquitylation of the target proteins
through inhibition of the ubiquitylation cascade components can also
counter the effects of ubiquitylation to achieve pathway ﬁne-tuning.
In the TGFβ pathway, both deubiquitylation and prevention of
ubiquitylation of the target proteins by deubiquitylating enzymes
have been reported as mechanisms to counter the effects of
ubiquitylation. We provide a thorough overview of the current
knowledge on the roles of deubiquitylating enzymes in the regula-
tion of the TGFβ/BMP pathways.
3.1. Deubiquitylating enzymes (DUBs)
DUBs are isopeptidases that remove ubiquitin chains or individual
ubiquitin molecules attached to their target proteins. Around 100 DUBs
are encoded in the human genome [35,36], which are classiﬁed into ﬁve
distinct structural groups based on their catalytic domains: i. ubiquitin-
speciﬁc proteases (USPs); ii. ubiquitin C-terminal hydrolases (UCHs); iii.
ovarian tumour proteases (OTUs); iv. Josephins; and v. JAB1/MPN/
MOV34 metalloenzymes (JAMM/MPN+) [35,36]. Members belonging
to the UCH, USP, OTU and Josephin families are cysteine proteases,
while those that belong to JAMM/MPN+family are zincmetalloproteases
[35,36].
The limited number of DUBs encoded by the human genome in com-
parison to the number of E3 ligases implies that catalytically DUBs are
potentially promiscuous. Therefore, the substrate speciﬁcity and activity
of DUBs have to be tightly regulated in order to ensure proper ubiquitin
processing and achieve normal homeostasis in cells. One could envisage
that this is achieved through conformational/post-translational modiﬁ-
cations on the DUBs or target proteins, speciﬁc interactions withregulatory partners or regulated sub-cellular location of the DUBs.
Indeed, enzymatic activity of DUBs can be concealed by occluding the
substrate-binding sites of certain DUBs and regulated by inducing
conformational changes that activate the catalytic site [35–40]. Apart
from their catalytic core, DUBs contain multiple domains that mediate
protein–protein interactions including ubiquitin-interacting motifs,
ubiquitin associated domains, ubiquitin binding domains or ubiquitin-
like folds and/or zinc ﬁnger ubiquitin-speciﬁc protease domains. These
domains contribute to the binding and recognition of different ubiquitin
chain linkages, although some DUBs also display direct afﬁnity for their
ubiquitylated target proteins [35–40]. Furthermore, substrates can be
ubiquitylated by different E3 ligases resulting in distinct ubiquitin
chains. Hence, DUBs also distinguish between ubiquitin-like molecules,
linear peptides, isopeptides and different types of ubiquitin linkage as
well as exo- versus endo-deubiquitylation [35–40].
The research on cellular roles and regulation of DUBs is an emerging
ﬁeld. The modes of action, physiological substrates and roles of most
DUBs are still poorly understood. The investigations of their roles in
the regulation of the TGFβ and BMP pathways have picked up pace in
the last ﬁve years and have uncovered several insightful mechanisms,
which are discussed below. A summary of all the DUBs reported so
far to regulate the components of the TGFβ and BMP pathways are
summarised in Table 1.
The USP family, which represents the most abundant group within
DUBs, is prominently reported to be involved in regulating the TGFβ
and BMP pathways, with USP4, USP11, USP15, USP18, USP9X and
CYLD all implicated. The UCH member UCH37, OTU members A20 and
OTUB1 and JAMM/JPN+member AMSH, are also reported to regulate
the TGFβ pathway.3.2. USP4, USP11 and USP15 target type I TGFβ receptors
for deubiquitylation in the TGFβ pathway
Among the USP family of DUBs, USP4, USP11 and USP15 are highly
similar and display conserved structural domains and protein se-
quences. They harbour a conserved DUSP (domain in USPs of unknown
function) at theN-terminus and two UBLs (ubiquitin like domains), one
preceding the USP catalytic domain and onewithin [35]. Intriguingly all
three of them were independently discovered as DUBs for the type I
TGFβ receptors through contrasting approaches (Fig. 2A). A gain-of-
function screen looking for activators of TGFβ signalling identiﬁed
USP4 [41], a proteomic approach looking at interactors of SMAD7 iden-
tiﬁed USP11 [42] and a siRNA loss-of-function screening looking for
DUBs affecting the TGFβ-induced luciferase reporter activity identiﬁed
USP15 [43].
USP4 has been reported to enhance TGFβ signalling by directly
interacting with and deubiquitylating type I TGFβ receptor, ALK5
[41]. In this study, it was reported that upon phosphorylation by
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Fig. 2. TGFβ/BMP receptor deubiquitylation. A) USP4, USP15, and USP11 have been identiﬁed to reverse the TGFβ receptor ubiquitylation, through distinct molecular mechanisms (see
text). It is not known whether these DUBs target the ligand-activated receptor complexes or just the type I receptors. B) USP15 binds to and targets the BMP type I receptor for
deubiquitylation. C) CYLD and AMSH/AMSH-LP are DUBs that reverse the ubiquitylation of I-SMADs, which in turn direct E3 ligases and DUBs to the receptors.
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ALK5, deubiquitylates it and protects it from destruction (Fig. 2A).
The AKT-mediated phosphorylation of USP4 also affects its stability
and DUB activity. Moreover, USP4 depletion inhibits TGFβ-induced
epithelial to mesenchymal transition (EMT) and AKT-induced breast
cancer cell migration [41].
USP11 was identiﬁed as an interactor of SMAD7 and ALK5. When
bound to ALK5, USP11 deubiquitylates and protects ALK5 from
proteasomal degradation resulting in enhanced TGFβ signalling.
Consequently, TGFβ-induced levels of phosphorylated SMAD2/3
and transcription were augmented (Fig. 2A). SMAD7, a transcrip-
tional target of TGFβ signals, negatively regulates the TGFβ pathway
by recruiting HECT E3 ubiquitin ligases and targeting TGFβ receptors
for ubiquitin-mediated degradation. USP11 could override the nega-
tive effects of SMAD7 on the TGFβ pathway, demonstrating that a
dynamic balance between ubiquitylation and deubiquitylation
could determine the fate of ALK5. It was shown that depletion of
USP11 resulted in inhibition of TGFβ-induced transcription as well
as EMT [42].
USP15 was reported to enhance TGFβ signalling by binding to the
SMAD7–SMURF2 complex and deubiquitylating ALK5 in the process
[43] (Fig. 2A). Moreover, USP15 ampliﬁcation was observed in glioblas-
toma, breast and ovarian cancers, which highly correlated with en-
hanced TGFβ signalling activity and poor prognostic outcomes in
individuals with glioblastoma [43]. Depletion of USP15 reduced the on-
cogenic capacity of patient-derived glioma-initiating cells through the
inhibition of TGF-β signalling, suggesting a direct role for USP15 and
TGFβ signalling in glioblastoma pathogenesis [43].
The roles of three very closely related DUBs on type I TGFβ receptors
pose interesting questions. Do these DUBs work in conjunction with
each other? Or could they act independently in the absence of others?The evidence from published reports suggests that both possibilities
are likely. The study that identiﬁed USP4 as a DUB for ALK5 also demon-
strated that phosphorylation of USP4 on S445 triggers homomeric and
heteromeric complex formation with USP11, USP15 and USP19, sug-
gesting that these DUBs could act as a complex [41]. Similarly, a size ex-
clusion analysis showing that USP11 elutes at a very high molecular
weight fraction also suggests its existence as part of a macromolecular
complex [42]. On the other hand, a recent study suggested that TGFβ
signalling was normal in T-cells derived from USP15-knockout mice
and in A375 and HCT116 cells upon USP15 depletion [44]. Similar ex-
periments in USP4 andUSP11 knockout cells (or knockin of catalytically
inactive mutants) will be important to determine whether these DUBs
play critical roles in deubiquitylating ALK5. Collectively, it is likely that
USP4, USP11 and USP15 act either as monomeric or heteromeric com-
plexes and in the prolonged absence of one or two members, the third
one could compensate for the loss of other two. Furthermore, the cell
type or context-dependent selectivity of one of these DUBs over the
others (e.g. the AKT phosphorylation site in USP4 is not conserved in
USP11 or USP15) is a possibility and needs to be investigated further.
3.3. USP15 targets type I BMP receptors for deubiquitylation in the
BMP pathway
In addition to its regulation of type I TGFβ receptors, USP15 has been
reported to act as a deubiquitylase for type I BMP receptors. USP15 was
shown to interact with SMAD6, a negative regulator of BMP signalling
(Fig. 2B). Further characterisation of the role of USP15 in the BMP
pathway established that USP15 enhances BMP-induced phos-
phorylation of SMAD1 and transcription. It was shown that USP15
interacts with type I BMP receptors, including ALK3, co-localises
with ALK3 at the membrane and deubiquitylates ALK3, thereby
2190 L. Herhaus, G.P. Sapkota / Cellular Signalling 26 (2014) 2186–2192countering the inhibition of the BMP pathway caused by SMAD6
[45]. This study further demonstrated that USP15 was critical for
BMP signalling in mammalian cells, mouse osteoblastic differentia-
tion and Xenopus embryogenesis. Interestingly, related DUBs USP4
and USP11 have been shown to have no effects on BMP signalling
[41,42,45]. A possible role for USP15 in BMP signalling was also
proposed by a genome-wide loss-of-function study of DUBs that
impact dorsoventral patterning during zebraﬁsh development
[46].
3.4. USP15 targets monoubiquitylated R-SMADs
Prior to its reported roles in deubiquitylating the type I TGFβ/BMP
receptors, USP15 was reported to interact with and deubiquitylate
monoubiquitylated R-SMADs, resulting in enhanced TGFβ and BMP sig-
nalling [47]. Monoubiquitylation of R-SMADs reportedly occurs at the
DNA-binding domain of R-SMADs, thereby preventing their association
with DNA at the promoters (Fig. 3). This report demonstrated that
USP15 was required for TGFβ and BMP responses in both mammalian
cells and Xenopus embryos [47]. Although the mechanisms by which
USP15 acts on TGFβ and BMP signalling proposed in this study differ
from those described above, the fundamental observations that USP15
enhances both TGFβ and BMP signalling are consistent with studies de-
scribed above [43,45]. As DUBs are promiscuous, it is possible that
USP15 acts by targeting multiple substrates to regulate TGFβ and BMP
signalling.
3.5. USP9X targets SMAD4 for deubiquitylation in the TGFβ pathway
A siRNA screening of DUBs identiﬁedUSP9X/FAMas aDUB that affect-
ed TGFβ-induced transcription of p21 without affecting phosphorylation
of SMAD3. Subsequently it was shown that USP9X deubiquitylates
SMAD4 that is monoubiquitylated at K519 (Fig. 3). It was shown thatSMAD4
USP9x
U
degradationpr
ot
ea
so
m
e
stabilisation
SMAD4
SMAD2/3
SMAD4
P
SMAD2/3
Fig. 3. SMAD deubiquitylation: USP9X and USP15 reverse the monoubiquitylation of SMAD4 an
efﬁcient transcription of TGFβ/BMP-mediated target genes. OTUB1 recognises TGFβ-activated S
TGFβ signalling.monoubiquitylationof SMAD4 inhibits transcriptionby impeding its asso-
ciation with phospho-SMAD2/3. Thus, USP9X enhances TGFβ signalling
by countering SMAD4 monoubiquitylation [48]. The study further dem-
onstrated that USP9X is required for TGFβ-induced growth arrest and cel-
lularmigration. Further evidence for the role of USP9X on TGFβ signalling
comes from two recent studies in Drosophila and mouse knockout
models. In Drosophila, the absence of fat facets (USP9X homologue) in-
hibits the activity of Medea (SMAD4 homologue) below the threshold
necessary for adequate decapentaplegic (BMP homologue) signalling
due in part to excessive ubiquitylation of Medea on K738 (equivalent of
human SMAD4 K519). The study further showed that the USP9X-
mediated stabilisation of SMAD4 was critical for regulation of the zygotic
BMP2/4 (decapentaplegic) morphogen gradient that determines dorsal–
ventral axis formation [49]. Similarly, in mice when USP9X was deleted
from neural progenitors, TGFβ-dependent axon genesis was inhibited
[50]. The levels of SMAD4 ubiquitylation in USP9X-null axons were not
tested in this study [50].
3.6. CYLD modulates SMAD7 and SMAD3 levels to inhibit TGFβ signalling
CYLD is a member of the USP DUBs that selectively hydrolyses K63-
linked polyubiquitin chains [51]. Enhanced levels of regulatory T cells
(Tregs), whose development is promoted by TGFβ signalling, were ob-
served in CYLD-knockout mice. Further characterisation showed that
CYLD controls the development of Tregs by deubiquitylating SMAD7,
thereby inhibiting TGFβ signalling (Fig. 2C). CYLD was shown to target
K63-linked ubiquitylation of SMAD7 at K360 and K374, which are
ubiquitylation sites required for the activation of TAK1 and p38MAP ki-
nases. Knockdown of SMAD7 or inhibition of p38 activity in primary T
cells hindered Treg differentiation, demonstrating that TGFβ signalling
in T cells and the development of Tregs are regulated by K63-linked
ubiquitylation of SMAD7 [52]. An alternative mechanism of how TGFβ
signalling is regulated by CYLD has also been proposed, again usingR-SMAD
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signalling by decreasing the stability of SMAD3 via the AKT–GSK3–
CHIP pathway. CYLD deubiquitylates K63-polyubiquitylated AKT,
resulting in the inhibition of AKT. This leads to activation of
GSK3β, which promotes CHIP-mediated SMAD3 degradation,
thereby inhibiting TGFβ signalling and ﬁbrotic responses [53].
Based on this study, it would be interesting to investigate whether
USP4 function, which is also modulated by AKT as described above,
is also affected in CYLD knockout mice [41,53].3.7. OTUB1 interacts with active SMAD2/3 and impacts TGFβ signalling
OTUB1, a member of the OTU family of DUBs, has been shown to
inhibit the ubiquitylation of only TGFβ-activated SMAD2/3 [54].
While OTUB1 cleaves K48-linked polyubiquitin chains, it has also
been shown to act in a non-canonical mode. The non-canonical
mode of action, where the catalytic activity of OTUB1 is dispensable,
relies on its interaction with ubiquitin charged-E2 and inhibition
mediated by the ubiquitin-binding motif in the N-terminus of
OTUB1 [55–62]. Binding to uncharged E2s on the other hand can in-
crease the catalytic activity of OTUB1 [63]. OTUB1 was identiﬁed as
an interactor of SMAD3 only under conditions where cells were
treated with TGFβ [54]. Further characterisation revealed that endoge-
nous OTUB1 is recruited to the active phospho-SMAD2/3 complex
only upon TGFβ induction. The phosphorylation of SMAD2/3 at the
C-terminus was necessary and sufﬁcient for the interaction with
OTUB1. It was shown that OTUB1 is critical for TGFβ-mediated gene
transcription and cellular migration. Interestingly, it was demonstrated
that OTUB1 stabilises the active SMAD2/3 complex by preventing the
ubiquitylation of phospho-SMAD2/3 through inhibition of the E2
ubiquitin-conjugating enzymes, independently of its catalytic activity
(Fig. 3). The ﬁndings from this study highlight the dynamic interplay
between phosphorylation and ubiquitylation processes in the regula-
tion of the TGFβ pathway [54].3.8. UCH37 (UCHL5) targets ALK5 in the TGFβ pathway
TheUCH family of DUBs consists of 4members that are primarily im-
plicated in polyubiquitin chain trimming/editing [64]. One of its mem-
bers, UCH37, has been reported to deubiquitylate the type I receptor
(ALK5) and sustain early TGFβ pathway activation [65,66]. UCH37 has
its catalytic domain in the N-terminus and harbours a coiled-coil do-
main at its C-terminus [35]. It has been shown that UCH37 is directed
to ALK5 via its interaction with SMAD7. UCH37 also weakly binds to
SMAD2 and 3, however it only deubiquitylates ALK5 andhencemodiﬁes
TGFβ-induced transcription [65]. UCH37 especially inﬂuences TGFβ-
mediated transcription during the early phase of TGFβ receptor activa-
tion. UCH37 knockdown decreases transcription of TGFβ-dependent
target genes and also slows lateral cell migration [66].3.9. The role of zinc metalloproteases AMSH and AMSH-LP in TGFβ and
BMP signalling
AMSH has been shown to interact with SMAD6 upon BMP receptor
activation [67]. It has been proposed that AMSH sequesters SMAD6,
thus impeding its inhibitory role on the BMP pathway and thereby
resulting in a prolonged BMP signalling. Similarly, AMSH-LP has been
reported to sequester SMAD7, thereby exerting a positive impact on
the TGFβ pathway (Fig. 2C) [68]. However, the roles of AMSH and
AMSH-LPDUB activity on BMP and TGFβ signallingwere not investigat-
ed at the time of their discoveries, partly because they had not been
established as DUBs at the time. AMSH and AMSH-LP have since been
reported to selectively deubiquitylate K63-ubiquitin chains [69].3.10. DUBs implicated in the regulation of non-canonical TGFβ signalling
Most DUBs implicated in the non-canonical TGFβ pathway have fo-
cussed primarily on the TRAF6–TAK1–p38 MAPK signalling axis. While
TGFβ induced p38 MAPK activation plays an important role in immune
signalling, the role of TAK1 on TGFβ-induced p38 MAPK has recently
been questioned [70]. USP4 has been reported to deubiquitylate TAK1
[71]. It was shown that TNFα induces the association of USP4 with
TAK1 and deubiquitylation of K63-linked ubiquitin chains from TAK1,
leading to the inhibition of NF-κB production. Similarly, USP4 inhibited
IL-1β-, LPS- and TGFβ-induced NF-κB production [71].
TGFβ together with IL-6 initiates T helper 17 (Th17) cell differentia-
tion [72]. Recently, USP18 has been shown to regulate T cell activation
and Th17 cell differentiation by associating with and deubiquitylating
the TAK1–TAB1 complex, thereby restricting IL-2 expression. USP18
knockoutmicewere found to be defective in Th17 generation and resis-
tant to experimental autoimmune encephalomyelitis. The negative reg-
ulation of TAK1 activity during Th17 differentiation by USP18, led the
authors to suggest USP18 as a target to treat autoimmune diseases [73].
A20 has been shown to be recruited to TRAF6 by SMAD6 and
abolish K63-linked polyubiquitylation of TRAF6, resulting in inhi-
bition of the TRAF6–TAK1–p38 MAPK/JNK pathway. Knockdown
of the deubiquitylating enzyme A20 or its transporter SMAD6, re-
sulted in increased apoptosis, while maintaining TAK1 and p38
MAPK/JNK phosphorylation, indicating that SMAD6 and A20 are
essential for the negative regulation of non-canonical TGFβ signal-
ling [74].
4. Perspective
The past ﬁve years have seen a huge surge on research reports and
interest on DUBs regulating the BMP and TGFβ pathways. While many
DUBs purported to play essential roles on the TGFβ and BMP pathways
have been discovered, the precise molecular details of their function,
substrate selectivity and regulation in the TGFβ and BMP pathways re-
main to be deﬁned in some cases. Several DUBs are known to regulate
the deubiquitylation of TGFβ and BMP type I receptors, R-SMADs,
SMAD4 and SMAD7. For the most part, we still do not know the precise
lysine residues on which the initial ubiquitin is attached and the type of
subsequent ubiquitylation chains, if any, that are formed. Furthermore,
precisely how selective DUBs are recruited to speciﬁc targets in the
TGFβ pathway is not completely understood. Different extra-cellular
signals and post-transcriptional modiﬁcations within the DUBs or tar-
gets are likely to tweak substrate recognition and catalytic activity of
DUBs. Further research needs to focus on identifying such signals
that modify DUB activity, their subcellular localisation and their se-
lection of substrates and investigate the importance of potential in-
terplay between PTMs (such as phosphorylation or acetylation)
and ubiquitylation.
As we have discussed above, various diseases are linked to the mal-
function of the TGFβ pathway. The ﬁndings that several DUBs target
components of the TGFβ and BMP pathways for deubiquitylation to
drive normal signalling imply that DUBs could be suitable candidate tar-
gets for the development of small molecule inhibitors of the TGFβ and
BMP pathways. Selective inhibitors of these DUBs could be potentially
useful therapeutically against pathologies associated with abnormal
TGFβ and BMP signalling. Furthermore, there are recent reports that
imply certain DUBs are themselves modiﬁed or mis-expressed in can-
cers [43] thereby affecting TGFβ signalling. While research projects
aiming to develop selective inhibitors of DUBs are underway, caution
needs to be taken, as each DUBwould be predicted to target many sub-
strates beyond TGFβ/BMP signalling. A better strategy would therefore
be to understand the molecular mechanisms bywhich a DUB is recruit-
ed to its target in the TGFβ and BMP pathways. This would allow for the
development of small molecules that selectively inhibit the interaction
between the DUB and its target in the TGFβ pathway but not other
2192 L. Herhaus, G.P. Sapkota / Cellular Signalling 26 (2014) 2186–2192targets. Indeed, the tail phosphorylation-dependent recruitment of
OTUB1 to SMAD2/3 is a case for which interaction determinants are
known [54].
Many studies reporting on discoveries of DUBs in the TGFβ and BMP
pathways have relied on RNAi strategies to investigate loss-of-function
impact. While RNAi strategies are useful tools, there are limitations
ranging from limited knockdowns of targets to potential off-target
effects. New and better technologies now exist that could and should
be harnessed to deﬁnitively establish the roles of selective DUBs in the
TGFβ and BMP pathways. Targeted DUB knockouts in cells (either
derived from knockout mice or using CRISPR/CAS9 technology [75,76]
to knockout genes in somatic cells) could allow for restoration of DUB
mutants lacking catalytic activity or substrate-interaction determinant.
Further issues of potential redundancy could be addressed in such sys-
tems. The next decade is sure to address the molecular mechanisms
by which DUBs regulate the TGFβ and BMP pathways.
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